In the gene-editing race, space is at a premium for Cambridge startup Intellia

... struck high-profile collaboration deals with Swiss drug giant Novartis AG and Regeneron Pharmaceuticals Inc . of Tarrytown, N.Y. It raised $108 million in an initial public offering in May. Its scientists are working feverishly on gene-editing ...
http://ift.tt/2dYu6SJ